In the present study, to evaluate the clinical significance of measures of serum C-peptide in achieving good glycemic control, we retrospectively analyzed the use of indices of endogenous insulin secretion in type 2 diabetes patients admitted to our hospital. Using data of patients who achieved the target of glycemic control during the period of admission, the patients were divided into two groups: one that achieved good control without the use of insulin (non-insulin group) and the other that required the use of insulin (insulin group), and the indices using serum C-peptide were compared between them. Optimal values and the utility of indices using serum C-peptide to select insulin therapy to achieve good glycemic control were analyzed.

MATERIALS AND METHODS

Subjects

A total of 746 Japanese patients with type 2 diabetes admitted between 2003 and 2009 to Kyoto University Hospital for poor glycemic control were enrolled in the present study. Type 2 diabetes mellitus was diagnosed based on the criteria of the American Diabetes Association (ADA)[15]. As indicated in Figure S1, 76 patients including those with pancreatic disease and liver disease, those taking diabetogenic medication and pregnant women were excluded. A total of 40 patients with incomplete clinical examinations also were excluded, and 66 patients with serum creatinine ≥ 1.3 mg/dL were excluded, as serum C-peptide immunoreactivity (CPR) is elevated by decreased renal function[16]. The data of 90 patients taking oral hypoglycemic agents (OHA) plus insulin at discharge were excluded. Good control was defined as mean preprandial capillary plasma glucose level <130 mg/dL, according to the glycemic control recommendation of ADA[17]. The 474 patients were divided into two groups: 201 patients who achieved good glycemic control (achieved group) and 273 patients who did not (non-achieved group). As shown in Figure S2, of the 201 patients in the achieved group, 47, 107, 38 and nine patients were treated with diet alone, OHA, insulin and insulin plus OHA at admission, respectively. At discharge, 24, 95 and 82 patients were treated with diet alone, OHA and insulin, respectively. Patients treated with diet alone and OHA at discharge comprised the non-insulin group; patients treated with insulin at discharge comprised the insulin group. A total of 166 patients of the 474 patients in the achieved or non-achieved group at discharge who could be confirmed within 6 months after discharge to achieve <7.4% in HbA$_{1c}$, which excludes 'not good' and 'poor' for assessment of glycemic control in the treatment guide for diabetes of the Japan Diabetes Society (JDS guide)[18], were re-analyzed to determine the cut-off point for C-peptide index (CPI) for longer duration of glycemic control. Of the 201 patients in the achieved group at discharge, 85 were excluded as a result of readmission or alteration to the mode of therapy, or were not followed as outpatients due to a change of hospital. Of the remaining 116 patients, 90 showed <7.4% HbA$_{1c}$ within 6 months after discharge. Of the 273 patients in the non-achieved group at discharge, 137 were excluded as a result

of readmission or alteration to the mode of therapy, or were not followed as outpatients due to a change of hospital. In the remaining 136 patients, 76 achieved <7.4% HbA$_{1c}$ within 6 months after discharge. In these 166 patients, analysis of optimal values and the utility of CPI during admission was carried out.

Methods

On the first day in hospital, medical history, physical examination and laboratory evaluation including glycosylated hemoglobin were carried out. HbA$_{1c}$ was measured using HPLC (HA-8180; Arcray, Kyoto, Japan). The HbA$_{1c}$ (%) value was estimated as an National Glycohemoglobin Standardization Program equivalent (%) calculated by the formula: HbA$_{1c}$ (%) = HbA$_{1c}$ (JDS) (%) + 0.4%, considering the relational expression of HbA$_{1c}$ (JDS) (%) measured by the previous Japanese standard substance and measurement methods and HbA$_{1c}$ (National Glycohemoglobin Standardization Program)[19]. β-cell function was evaluated within 1 week after overnight fast by glucagon test measuring CPR before (fasting CPR [FCPR]) and 6 min after i.v. injection of 1 mg glucagon (CPR-6 min)[7], as this test is valid in patients taking insulin therapy. Increment of CPR (ΔCPR) was obtained by subtracting FCPR from CPR-6 min. SUIT index (SUIT) (%) was calculated by the formula: $1500 \times$ FCPR (ng/mL)/(fasting plasma glucose [FPG; mg/dL] $-$ 61.7)[20]. CPI (ng/mg) was calculated by the formula: $100 \times$ FCPR (ng/mL)/FPG (mg/dL). Serum CPR was measured by immunoenzymometric assay (EIA; ST AIA-PACK C-Peptide, Toso corporation, Tokyo, Japan). In patients taking OHA, medication was stopped for the glucagon test, but was maintained until 1 day before to prevent hyperglycemia during the test[6]. Fasting plasma glucose was measured by the glucose oxidase method when the glucagon test was carried out. Patients were treated according to the JDS guide[18]. Treatment policy including diet therapy, exercise therapy, pharmacotherapy and education for each patient was determined by Japanese Board Certified Diabetologists certified by the Japan Diabetes Society. Patients took medical nutritional therapy (25–30 kcal/kg of standard bodyweight/day consisting of 58% carbohydrate, 18% protein and 24% fat energy intake percentages) with counseling by a registered dietitian. Preprandial capillary plasma glucose levels were monitored three t.i.d. during hospitalization. The study protocol was approved by the ethics committee of Kyoto University.

Statistical analysis

Statistical analysis was carried out with the Stat View 5.0 system (SAS institute, Cary, NC, USA). Data are presented as mean $\pm$ SE unless otherwise stated. Clinical parameters among the two groups were compared by Mann–Whitney U-test. P-values <0.01 were considered statistically significant. Histograms and receiver–operator characteristic (ROC) curve were made for FCPR, CPR-6 min, ΔCPR, SUIT and CPI respectively, and sensitivity, specificity, cut-off values, area under the ROC curve (AUC) and the likelihood ratio were calculated.

RESULTS

Clinical profiles of patients with mean preprandial capillary plasma glucose levels at discharge of <130 mg/dL (achieved group) and ≥130 mg/dL (non-achieved group), respectively, are shown in Table 1. Patients of the non-achieved group were older, had lower body mass index at admission, higher mean preprandial capillary plasma glucose level both at admission and at discharge, longer years from diagnosis and lower endogenous insulin secretion indices than those of the achieved group. The clinical stages of diabetic nephropathy and retinopathy were more progressed in the non-achieved group than those in the achieved group. The relationships between indices using serum C-peptide and selected modes of therapy at discharge were analyzed based on the data of the achieved group.

The clinical profiles of patients not requiring insulin for good glycemic control (non-insulin group) and those requiring insulin (insulin group) are shown in Table 2. The patients of the insulin group were older, has lower body mass index, higher HbA_{1c} at admission, higher mean preprandial capillary plasma glucose level at admission, longer years from diagnosis and lower endogenous insulin secretion indices compared with those of the non-insulin group. As shown in Figure S2, the mode of therapy in 41 patients was altered from diet alone or OHA to insulin during admission. The average number of hospital days before altering the therapeutic mode of these patients was

3.1 ± 3.4 (mean ± SD). The reasons for the change to insulin therapy were the necessity of tight glycemic control before operation in five patients, marked hyperglycemia (a fasting plasma glucose level of 250 mg/dL or above, or a causal plasma glucose of 350 mg/dL or above)[21] or both the presence of hyperglycemia and ketosis in 11 patients, and persistent hyperglycemia with OHA in 25 patients. HbA_{1c} at admission of these patients was 10.2 ± 2.2% (mean ± SD). In five patients, the mode of therapy was altered from insulin to OHA. The average number of hospital days before this change was 7.6 ± 4.3 (mean ± SD); the reason was improved glycemic control despite a decrease in the required dosage of insulin. HbA_{1c} at admission of these patients was 10.1 ± 4.4% (mean ± SD). Another patient treated with OHA plus insulin at admission was changed to OHA alone after nine hospital days because of improved glycemic control. Of the 113 patients with therapy of diet alone or OHA both at admission and at discharge, 19 transiently used insulin during the period of admission.

The category of OHA at discharge is shown in Table S1a. In 95 patients treated with OHA, 60 and 29 patients were prescribed sulfonylurea alone or in combination, and biguanide alone or in combination, respectively. In the insulin group, 50 of 86 patients were given premixed insulin b.i.d. at discharge. As shown in Table S1b, the prescribed daily dosages of gliclazide, glimepiride and metformin required were <80, 4 and 750 mg,

Table 1 | Clinical profiles of patients who achieved good glycemic control

	Achieved	Non-achieved	P
No. subjects	201	273	
Duration of hospitalization (days)	22.0 ± 0.7	23.6 ± 0.7	0.1115
Age (years)	60.2 ± 0.9	64.5 ± 0.7*	0.0002
Male/female	127/74	159/114	
Systolic blood pressure (mmHg)	124.5 ± 1.0	126.9 ± 1.1	0.1076
Diastolic blood pressure (mmHg)	74.6 ± 0.7	73.6 ± 0.6	0.2653
BMI (kg/m²)	25.2 ± 0.3	23.8 ± 0.3*	0.0005
HbA_{1c} at admission (%)	9.5 ± 0.1	9.8 ± 0.1	0.0776
PG at admission (mg/dL)	181.1 ± 4.7	209.5 ± 3.9*	<0.0001
PG at discharge (mg/dL)	112.2 ± 0.9	163.2 ± 1.9*	<0.0001
Years from diagnosis	9.1 ± 0.6	13.5 ± 0.6*	<0.0001
FCPR (ng/mL)	1.87 ± 0.06	1.65 ± 0.05*	0.0054
CPR-6 min (ng/mL)	3.99 ± 0.14	3.41 ± 0.10*	0.0006
ΔCPR (ng/mL)	2.12 ± 0.09	1.76 ± 0.07*	0.0011
SUIT (%)	40.6 ± 1.9	32.4 ± 2.0*	0.0043
CPI (ng/mg)	1.34 ± 0.05	1.09 ± 0.04*	<0.0001
Clinical stage of nephropathy (normal/microalbuminuria/macroalbuminuria)	129/56/16 (64/28/8)	133/80/60 (49/29/22)	
Clinical stage of retinopathy (NDR/mild NPDR/moderate NPDR/severe NPDR/PDR)	141/25/26/4/5 (71/12/13/2/2)	112/53/45/22/41 (41/20/16/8/15)	

Data are presented as mean ± SE. *P < 0.01 versus achieved. Achieved group: mean preprandial capillary plasma glucose levels at discharge <130 mg/dL compared with those who did not achieve good glycemic control (non-achieved group ≥130 mg/dL). BMI, body mass index; CPI, C-peptide index; ΔCPR, increment of C-peptide immunoreactivity; CPR-6 min, C-peptide immunoreactivity 6 min after intravenous injection of glucagon; FCPR, fasting C-peptide immunoreactivity; NDR, no diabetic retinopathy; NPDR, non-proliferative diabetic retinopathy; PDR, proliferative diabetic retinopathy; PG, mean preprandial capillary plasma glucose level; SUIT, secretory unit of islet in transplantation index. Numbers in parentheses indicate percentages.

Table 2 | Clinical profiles of patients who achieved good glycemic control without requiring the use of insulin and those requiring insulin to achieve good glycemic control

	Non-insulin	Insulin	P
No. subjects	119	82	
Male/female	82/37	45/37	
Age (years)	58.4 ± 1.1	62.9 ± 1.3*	0.0099
Systolic blood pressure (mmHg)	124.4 ± 1.4	126.4 ± 1.7	0.3598
Diastolic blood pressure (mmHg)	77.3 ± 1.0	73.3 ± 1.3	0.0135
BMI (kg/m²)	26.0 ± 0.4	24.0 ± 0.4*	0.0019
HbA₁c at admission (%)	9.2 ± 0.2	10.0 ± 0.2*	0.0050
PG at admission (mg/dL)	163.2 ± 5.0	206.9 ± 8.0*	<0.0001
PG at discharge (mg/dL)	110.9 ± 1.2	114.2 ± 1.3	0.0602
Years from diagnosis	7.8 ± 0.6	10.9 ± 1.0*	0.0052
FCPR (ng/mL)	2.06 ± 0.07	1.61 ± 0.09*	0.0001
CPR-6 min (ng/mL)	4.48 ± 0.18	3.29 ± 0.19*	<0.0001
ΔCPR (ng/mL)	2.43 ± 0.12	1.68 ± 0.12*	<0.0001
SUIT (%)	47.2 ± 2.5	31.1 ± 2.7*	<0.0001
CPI (ng/mg)	1.57 ± 0.07	1.06 ± 0.06*	<0.0001

Data are presented as mean ± SE. *P < 0.01 versus non-insulin. Good glycemic control: mean preprandial capillary plasma glucose levels at discharge <130 mg/dL.
BMI, body mass index; CPI, C-peptide index; ΔCPR, increment of C-peptide immunoreactivity; CPR-6 min, C-peptide immunoreactivity 6 min after intravenous injection of glucagon; FCPR, fasting C-peptide immunoreactivity; PG, mean preprandial capillary plasma glucose level; SUIT, secretory unit of islet in transplantation index.

respectively in almost all (more than 95%) patients. Daily insulin dosage was 22.0 ± 11.1 U (mean ± SD) in the insulin group.

In Figure S3, peak relative frequency of indices using CPR of patients with mean preprandial capillary plasma glucose levels of <130 mg/dL at discharge in the insulin group and the non-insulin group, respectively, is shown (FCPR: 1.50–1.75, 2.00–2.25 ng/mL; CPR-6 min: 2.75–3.00, 4.00–4.25 ng/mL; ΔCPR: 1.25–1.50, 1.25–1.50 plus 2.25–2.50 ng/mL; SUIT: 15–20, 25–30 plus 35–40 plus 45–50%; and CPI: 0.8–0.9, 1.5–1.6 ng/mg). According to ROC curves of indices using CPR shown in Figure 1, AUC, cut-off values and values at optimal cut-off points including sensitivity, specificity and the likelihood ratio were determined and shown in Table 3. CPI is the most relevant of these indices for selecting insulin therapy to achieve good glycemic control, because the likelihood ratio and AUC of CPI is greatest.

The ROC curve of CPI of patients who achieved <7.4% HbA₁c within 6 months after discharge is shown in Figure 2. According to ROC curves of CPI in Figure 2, the AUC (0.75), cut-off values (optimal: 1.2; 90% specificity 0.8; 90% sensitivity 1.7 ng/mg), and values at optimal cut-off points including sensitivity (73%), specificity (71%) and the likelihood ratio (2.5) were determined.


Figure 1 | Receiver–operator characteristic curves of (a) fasting C-peptide immunoreactivity (FCPR), (b) CPR 6 min after intravenous injection of glucagon (CPR-6 min), (c) increment of CPR (ΔCPR), (d) secretory unit of islet in transplantation index (SUIT) and (e) C-peptide index (CPI) of patients with mean preprandial capillary plasma glucose levels of <130 mg/dL at discharge.

DISCUSSION
Medical nutritional therapy (MNT) improves glycemic control in patients with type 2 diabetes regardless of their modes of therapy including diet alone, OHA and insulin[22–24]. Diet therapy is the basis and starting point of treatment of all patients with diabetes[25], and failure of diet therapy alone might predict the inability to attain optimal glycemic control by any of these modes of therapy. To precisely analyze the relationship between endogenous insulin secretion and the appropriate mode of therapy for achieving good glycemic control, we used data of hospitalized patients under optimal therapy including proper MNT. Thus, our results are more likely to be valid in patients with appropriate care behaviors. Although inappropriate care behavior is an obstacle to achieving good glycemic control over a longer duration, our results suggest a basis for beginning insulin therapy in patients who do not achieve good glycemic control with diet alone or OHA despite the practice of appropriate care behavior.

Table 3 | Analysis of indices using serum C-peptide of patients with mean preprandial capillary plasma glucose levels of <130 mg/dL at discharge

	FCPR	CPR-6 min	ΔCPR	SUIT	CPI
AUC	0.69	0.71	0.69	0.72	0.75
Cut-off values	(ng/mL)	(ng/mL)	(ng/mL)	(%)	(ng/mg)
Optimal	1.75	3.75	2.25	30	1.1
90% Specificity	1.00	2.25	1.00	20	0.7
90% Sensitivity	2.75	5.25	3.25	55	1.7
Values at optimal cut-off points					
Sensitivity (%)	70	74	82	61	61
Specificity (%)	66	65	49	73	78
Likelihood ratio	2.0	2.1	1.6	2.3	2.8

AUC, area under receiver–operator characteristics curve; CPI, C-peptide index; ΔCPR, increment of C-peptide immunoreactivity; CPR-6 min, C-peptide immunoreactivity 6 min after intravenous injection of glucagon; FCPR, fasting C-peptide immunoreactivity; SUIT, secretory unit of islet in transplantation index

Figure 2 | Receiver–operator characteristic curve of C-peptide index (CPI) of patients who achieved <7.4% HbA_{1c} within 6 months after discharge.

In the present study, just 42% of patients achieved good control during hospital admission, partly because the aim of admission was not necessarily to achieve good control during the period of admission, but to establish a treatment policy for the achievement of good control after discharge. The percentage of patients treated with insulin at discharge was higher in the non-achieved group than in the achieved group (non-achieved group: 67%; achieved group: 41%). Of the patients treated with OHA at admission in the achieved group, 39% had therapy changed to insulin, whereas 73% of the patients treated with OHA at admission in the non-achieved group had therapy changed to insulin. These results might indicate more intensive therapy in the case of the non-achieved group. Of the 136 patients in the non-achieved group at discharge, 76 showed

<7.4% HbA_{1c} within 6 months after discharge, showing fair glycemic control in some of the patients of this group over the longer term. As shown in Table 1, the non-achieved group had more progressive diabetic complications and more years from diagnosis compared with the achieved group. These factors might prompt therapy that aims at a more gradual improvement of glycemic control to prevent hypoglycemia. In addition, the non-achieved group showed higher glycemic levels at admission than that of the achieved group, whereas the duration of hospitalization was similar.

Although there have been several reports regarding the utility of indices of endogenous insulin secretion to indicate initiation of insulin therapy to improve glycemic control[11–14], none has compared the utility of the various indices. In the present study, as shown by the likelihood ratio and by AUC, CPI is shown to be the most useful among the five indices.

CPI was used as an index of endogenous insulin secretion in several reports[26–28], but its advantage over other indices and the scientific basis was unclear. The SUIT index (SUIT) was developed using FCPR and plasma glucose level after islet transplantation[19]. The linear relationship between FCPR and FPG in individual subjects shows a plasma glucose level (61.7 mg/dL) assumed to suppress C-peptide to zero. Transplantation of islets from non-diabetic donors increases the slope (FCPR/ [FPG − 61.7]), suggesting an index of transplanted β-cell mass. Although a correlation between SUIT and CPR 6 min after intravenous injection of 1 mg glucagon (CPR-6 min) is observed in type 2 diabetes ($r = 0.58$), it is weaker than that in patients after islet transplantation ($r = 0.82$)[19].

Autopsy reveals that β-cell mass is decreased in patients with type 2 diabetes compared with that in healthy subjects[29–31]. Recently, in 33 subjects at various stages of glucose tolerance, a correlation between β-cell areas of a sample obtained during pancreatectomy, and serum levels of CPR and insulin before the operation was analyzed[32]. Interestingly, β-cell areas are positively correlated with fasting insulin/FPG ($r = 0.51$, $P = 0.0024$) and FCPR/FPG ($r = 0.63$, $P < 0.0001$), but are not significantly

correlated with homeostasis model assessment β-cell function (HOMA-β). Because SUIT resembles HOMA-β in that insulin secretion is assumed to be suppressed to zero at approximately 60 mg/dL glucose in the formula, CPI might be a better index of residual β-cell mass than SUIT in subjects with glucose intolerance. Furthermore, CPI is not affected by exogenous insulin[27], which might favor reproducibility of the results in patients with insulin therapy. Determination of the index using a one-point blood sample without the use of loading agents also favors CPI.

In results derived from CPI of patients with mean preprandial capillary plasma glucose levels of <130 mg/dL at discharge, AUC was 0.75, optimal cut-off value was 1.1 ng/mg with 61% sensitivity and 78% specificity, and values at 90% sensitivity and at 90% specificity were 1.7 and 0.7 ng/mg, respectively. Interestingly, in results derived from CPI of patients who achieved <7.4% HbA$_{1c}$ within 6 months after discharge, AUC was 0.75, optimal cut-off value was 1.2 ng/mg with 73% sensitivity and 71% specificity, and values at 90% sensitivity and at 90% specificity were 1.7 and 0.8 ng/mg, respectively, similar to the values evaluated by mean preprandial glucose levels at discharge. These values are also similar to those in a previous report in Japanese using the data of 180 subjects from another institution (optimal cut-off value: 1.0 with 62% sensitivity and 81% specificity; values at 90% sensitivity: 1.8; 90% specificity: 0.7 ng/mg), although good glycemic control was defined as 8.4% in HbA$_{1c}$, which is somewhat inadequate[14]. Thus, CPI might be a predictor of suitable therapy to achieve fair glycemic control not only for the short-term, but also for longer duration.

The main limitation of the present study is that it is a retrospective analysis of inpatients at one hospital, and the protocol for starting insulin therapy was not defined precisely. However, in the achieved group analyzed as subjects, the decisions as to whether to start insulin therapy made by Japanese Board Certified Diabetologists were confirmed retrospectively to have been made according to the treatment guide for diabetes of the Japan Diabetes Society, as discussed in the results section.

In conclusion, we have shown the advantage of CPI of indices using CPR to select insulin therapy to achieve good glycemic control. However, limitations of the predictive abilities of indices using CPR generally and the importance of observation of the clinical therapeutic course must be taken into consideration.

ACKNOWLEDGEMENTS

REFERENCES

1. DeFronzo RA. Lilly lecture 1987. The triumvirate: β-cell, muscle, liver. A collusion responsible for NIDDM. *Diabetes* 1988; 37: 667–687.
2. Yki-Järvinen H, Kauppila M, Kujansuu E, *et al.* Comparison of insulin regimens in patients with non-insulin-dependent diabetes mellitus. *N Engl J Med* 1992; 327: 1426–1433.
3. Turner RC, Cull CA, Frighi V, *et al.* Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. *JAMA* 1999; 281: 2005–2012.
4. Japan Diabetes Society. Diabetes mellitus: the disease itself. In: Japan Diabetes Society (ed.). *Treatment Guide for Diabetes 2007*. Bunkodo, Japan, 2007; 8–13.
5. U.K. Prospective Diabetes Study Group. U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. *Diabetes* 1995; 44: 1249–1258.
6. Funakoshi S, Fujimoto S, Hamasaki A, *et al.* Analysis of factors influencing pancreatic β-cell function in Japanese patients with type 2 diabetes: association with body mass index and duration of diabetic exposure. *Diabetes Res Clin Pract* 2008; 82: 353–358.
7. Faber OK, Binder C. C-peptide response to glucagon. A test for the residual β-cell function in diabetes mellitus. *Diabetes* 1977; 26: 605–610.
8. Hendriksen C, Faber OK, Drejer J, *et al.* Prevalence of residual B-cell function in insulin-treated diabetics evaluated by the plasma C-peptide response to intravenous glucagon. *Diabetologia* 1977; 13: 615–619.
9. Jayyab AK, Heding LG, Czyzyk A, *et al.* Serum C peptide and IRI levels after administration of glucagon and glucose in non-insulin-dependent diabetics. *Horm Metab Res* 1982; 14: 112–116.
10. Gjessing HJ, Damsgaard EM, Matzen LE, *et al.* Reproducibility of β-cell function estimates in non-insulin-dependent diabetes mellitus. *Diabetes Care* 1987; 10: 558–562.
11. Madsbad S, Krarup T, McNair P, *et al.* Practical clinical value of the C-peptide response to glucagon stimulation in the choice of treatment in diabetes mellitus. *Acta Med Scand* 1981; 210: 153–156.
12. Sanke T, Satogami E, Sowa R, *et al.* Plasma C-peptide response during glucagon test as an index for evaluation of insulin requirement in diabetics (in Japanese). *J Jpn Diab Soc* 1985; 28: 713–719.
13. Koskinen P, Viikari J, Irjala K, *et al.* C-peptide determination in the choice of treatment in diabetes mellitus. *Scand J Clin Lab Invest* 1985; 45: 589–597.
14. Asano T, Kawamura M, Watanabe T, *et al.* Indices of urinary and serum C-peptide corrected with fasting plasma glucose for decision-making of insulin therapy in type 2 diabetes-validation and comparison (in Japanese). *J Jpn Diab Soc* 2008; 51: 759–763.
15. American Diabetes Association. Diagnosis and classification of diabetes mellitus. *Diabetes Care* 2010; 33: S62–S69.
16. Kajinuma H, Tanabashi S, Ishiwata K, *et al.* Urinary excretion of C-peptide in relation to renal function. In: Baba S (ed.). *Proinsulin, Insulin, C-Peptide.* Excerpta Medica, Amsterdam, 1979; 183–189.
17. American Diabetes Association. Standards of medical care in diabetes-2010. *Diabetes Care* 2010; 33: S11–S61.
18. Japan Diabetes Society (ed.). *Treatment Guide for Diabetes 2007*. Bunkodo, Japan, 2007.

- 362 -

19. The Committee of Japan Diabetes Society on the diagnostic criteria of diabetes mellitus. Report of the Committee on the classification and diagnostic criteria of diabetes mellitus. *J Diabetes Invest* 2010; 1: 212–228.

20. Yamada Y, Fukuda K, Fujimoto S, *et al.* SUIT, secretory units of islets in transplantation: an index for therapeutic management of islet transplanted patients and its application to type 2 diabetes. *Diabetes Res Clin Pract* 2006; 74: 222–226.

21. Japan Diabetes Society. Insulin treatment. In: Japan Diabetes Society (ed.). *Treatment Guide for Diabetes 2007*. Bunkodo, Japan, 2007; 47–55.

22. Franz MJ, Monk A, Barry B, *et al.* Effectiveness of medical nutrition therapy provided by dietitians in the management of non-insulin-dependent diabetes mellitus: a randomized, controlled clinical trial. *J Am Diet Assoc* 1995; 95: 1009–1017.

23. Ziemer DC, Berkowitz KJ, Panayioto RM, *et al.* A simple meal plan emphasizing healthy food choices is as effective as an exchange-based meal plan for urban African Americans with type 2 diabetes. *Diabetes Care* 2003; 26: 1719–1724.

24. Miller CK, Edwards L, Kissling G, *et al.* Nutrition education improves metabolic outcomes among older adults with diabetes mellitus: results from a randomized controlled trial. *Prev Med* 2002; 34: 252–259.

25. Japan Diabetes Society. Diet therapy. In: Japan Diabetes Society (ed.). *Treatment Guide for Diabetes 2007*. Bunkodo, Japan, 2007; 34–37.

26. Park SW, Ihm SH, Yoo HJ, *et al.* Differential effects of ambient blood glucose level and degree of obesity on basal serum C-peptide level and the C-peptide response to glucose and glucagon in non-insulin-dependent diabetes mellitus. *Diabetes Res Clin Pract* 1997; 37: 165–171.

27. Albareda M, Rigla M, Rodríguez-Espinosa J, *et al.* Influence of exogenous insulin on C-peptide levels in subjects with type 2 diabetes. *Diabetes Res Clin Pract* 2005; 68: 202–206.

28. Peacock I, Tattersall RB. The difficult choice of treatment for poorly controlled maturity onset diabetes: tablets or insulin? *Br Med J (Clin Res Ed)* 1984; 288: 1956–1959.

29. Sakuraba H, Mizukami H, Yagihashi N, *et al.* Reduced beta-cell mass and expression of oxidative stress-related DNA damage in the islet of Japanese Type II diabetic patients. *Diabetologia* 2002; 45: 85–96.

30. Butler AE, Janson J, Bonner-Weir S, *et al.* β-cell deficit and increased β-cell apoptosis in humans with type 2 diabetes. *Diabetes* 2003; 52: 102–110.

31. Rahier J, Guiot Y, Goebbels RM, *et al.* Pancreatic β-cell mass in European subjects with type 2 diabetes. *Diabetes Obes Metab* 2008; 10: 32–42.

32. Meier JJ, Menge BA, Breuer TG, *et al.* Functional assessment of pancreatic β-cell area in humans. *Diabetes* 2009; 58: 1595–1603.

SUPPORTING INFORMATION

Additional Supporting Information may be found in the online version of this article:

Figure S1 | Process of selection of subjects for analysis.

Figure S2 | Therapeutic modes of analyzed patients at admission and discharge, and the required alteration of therapy during the period of admission.

Figure S3 | Relative frequency distribution of C-peptide indices of patients with mean preprandial capillary plasma glucose levels of <130 mg/dL at discharge in the non-insulin and insulin group.

Table S1 | Details of medication and daily dosages of oral hypoglycemic agents used at discharge

Please note: Wiley-Blackwell are not responsible for the content or functionality of any supporting materials supplied by the authors. Any queries (other than missing material) should be directed to the corresponding author for the article.

Beneficial Effects of Exendin-4 on Experimental Polyneuropathy in Diabetic Mice

Tatsuhito Himeno,[1] Hideki Kamiya,[1,2] Keiko Naruse,[3] Norio Harada,[4] Nobuaki Ozaki,[1] Yusuke Seino,[1] Taiga Shibata,[1] Masaki Kondo,[1] Jiro Kato,[1] Tetsuji Okawa,[1] Ayako Fukami,[1] Yoji Hamada,[5] Nobuya Inagaki,[4] Yutaka Seino,[6] Daniel J. Drucker,[7] Yutaka Oiso,[1] and Jiro Nakamura[1]

OBJECTIVE—The therapeutic potential of exendin-4, an agonist of the glucagon-like peptide-1 receptor (GLP-1R), on diabetic polyneuropathy (DPN) in streptozotocin (STZ)-induced diabetic mice was investigated.

RESEARCH DESIGN AND METHODS—The presence of the GLP-1R in lumbar dorsal root ganglion (DRG) was evaluated by immunohistochemical analyses. DRG neurons were dissected from C57BL6/J mice and cultured with or without Schwann cell–conditioned media in the presence or absence of GLP-1 (7–37) or exendin-4. Then neurite outgrowth was determined. In animal-model experiments, mice were made diabetic by STZ administration, and after 12 weeks of diabetes, exendin-4 (10 nmol/kg) was intraperitoneally administered once daily for 4 weeks. Peripheral nerve function was determined by the current perception threshold and motor and sensory nerve conduction velocity (MNCV and SNCV, respectively). Sciatic nerve blood flow (SNBF) and intraepidermal nerve fiber densities (IENFDs) also were evaluated.

RESULTS—The expression of the GLP-1R in DRG neurons was confirmed. GLP-1 (7–37) and exendin-4 significantly promoted neurite outgrowth of DRG neurons. Both GLP-1R agonists accelerated the impaired neurite outgrowth of DRG neurons cultured with Schwann cell–conditioned media that mimicked the diabetic condition. At the doses used, exendin-4 had no effect on blood glucose or HbA_{1c} levels. Hypoalgesia and delayed MNCV and SNCV in diabetic mice were improved by exendin-4 without affecting the reduced SNBF. The decreased IENFDs in sole skins of diabetic mice were ameliorated by exendin-4.

CONCLUSIONS—Our findings indicate that exendin-4 ameliorates the severity of DPN, which may be achieved by its direct actions on DRG neurons and their axons. *Diabetes* 60:2397–2406, 2011

Diabetes is the most common cause of peripheral neuropathy encompassing both mononeuropathy and polyneuropathy (1,2). In general, diabetic polyneuropathy (DPN) develops symmetrically in a nerve length–dependent fashion, with dying-back degeneration of both myelinated and unmyelinated fibers. Diabetic patients may exhibit various symptoms of DPN, such as spontaneous pain, hyperalgesia, and diminished sensation (3). It has been shown that tight glycemic control is effective in slowing the progression of DPN but cannot completely prevent it (4). We have focused on the role of reduced nerve blood flow in the development and the progression of DPN (5–7). In addition to the hemodynamic deterioration of diabetic nerves, previous studies have described a number of pathogenic mechanisms suggesting favorable treatments of DPN, but these treatments have generally failed in clinical trials (2). Thus, at this time, there are few effective therapies for DPN. Because the etiology of DPN seems to be multifactorial, a multitargeted intervention may be necessary.

An incretin hormone, glucagon-like peptide (GLP)-1, is released from the L cells of the small intestine (8). GLP-1 and a GLP-1 receptor (GLP-1R) agonist, exendin-4, potentiate glucose-stimulated insulin secretion after a meal, and GLP-1R agonists have been used as therapeutic agents for type 2 diabetes (9–11). In addition to this antihyperglycemic effect, GLP-1R agonists have been shown to have several actions, such as slowing gastric emptying (11) and reducing food intake (12), that are independent of insulin secretion (13). Many reports have suggested that GLP-1R agonists have neurotrophic and neuroprotective properties in some neurons and neural cells (14–18). It has been revealed that prolonged neurite extension is induced by mechanisms involving cAMP (19), which also is involved in the cascade mechanisms of insulin secretion induced by GLP-1R agonists. In addition, the therapeutic effects of GLP-1R agonists on stroke, Parkinsonism, and pyridoxine-induced peripheral sensory neuropathy (18–20) using animal models have been reported.

Although several beneficial effects of GLP-1 or the GLP-1R agonist on central and peripheral nervous systems have been reported, their effects under the diabetic condition have not yet been evaluated. Here, we investigated the effects of the GLP-1R agonist exendin-4 on DPN by both in vitro and in vivo experiments.

RESEARCH DESIGN AND METHODS

Schwann cell culture and preparation of Schwann cell–conditioned media. Immortalized Schwann cells (IMS32), established by long-term culture of adult mouse dorsal root ganglions (DRGs) and peripheral nerves (21), were a gift from Dr. Kazuhiro Watabe. IMS32 were cultured in Dulbecco's

FIG. 1. Expression of GLP-1R in DRGs and sciatic nerves. *A*, *C*, *D*, and *F*: Immunohistochemically, GLP-1R (green) in DRG was detected with anti–GLP-1R antibody (sc-66911). Both DRG neurons, indicated by NF70 antibody (red) (*E* and *F*), and satellite glia cells, indicated by S100b antibody (red) (*B* and *C*), expressed GLP-1R. *C*, *F*, and *G*: Nuclei (blue) were stained with diaminido phenyl indol. *A–F*: White arrowheads indicate satellite glia cells. White arrows indicate neurons. *G*: GLP-1R protein (red) was not detected in DRG neurons of *glp1r*$^{-/-}$ mice. *H*: The transcript levels of *glp1r* in DRGs and sciatic nerves of diabetic mice were not significantly different from those of normal mice (DRG: normal mice [N] [*n* = 6], 1 ± 0.54, threshold cycle value [C_t] of *glp1r* 34.8 ± 2.3, C_t of 18S rRNA 11.2 ± 1.0 and diabetic mice [DM] [*n* = 7], 0.65 ± 0.23, C_t of *glp1r* 34.0 ± 1.5, C_t of 18S rRNA 11.0 ± 1.4, *P* = 0.544; sciatic nerves: normal mice [*n* = 4], 1 ± 0.34, C_t of *glp1r* 33.6 ± 1.6, C_t of 18S rRNA 14.7 ± 1.1 and diabetic mice [*n* = 5], 1.95 ± 1.29, C_t of *glp1r* 34.5 ± 1.3, C_t of 18S rRNA 12.5 ± 2.8, *P* = 0.606). *I*: There were no significant differences in the protein levels of GLP-1R

- 365 -

FIG. 2. Neurite outgrowth of DRG neurons by GLP-1 (7–37) and exendin-4 (Ex4). Representative fluorescence micrograph of DRG neurons cultured in the absence (A) or presence (B) of GLP-1 (7–37) (GLP-1) (10 nmol/L). GLP-1 (7–37) (10 nmol/L) or exendin-4 (0.1, 1, 10, and 100 nmol/L) increased the total neurite length (C) and joint number (D) of neurites. Results are means ± SD. CON, control medium. *$P < 0.05$ vs. control medium (n = 10–20). Control medium, joint number 23.5 ± 17.2 per cell, total length 833 ± 462 μm per cell, 10 nmol/L GLP-1 (7–37); joint number 54.8 ± 58.3, total length 2,786 ± 2,976, 0.1 nmol/L exendin-4; joint number 19.81 ± 29.59, total length 1,056.3 ± 904.5, 1 nmol/L exendin-4; joint number 32.23 ± 29.35, total length 761.9 ± 414.7, 10 nmol/L exendin-4; joint number 78.1 ± 58.4, total length 2,035 ± 1,162, 100 nmol/L exendin-4; and joint number 63.1 ± 33.8, total length 2,329 ± 1,104. (A high-quality digital representation of this figure is available in the online issue.)

modified Eagle's medium (DMEM) (Sigma-Aldrich, St. Louis, MO) containing 5.5 mmol/L D-glucose, penicillin (100 units/mL)-streptomycin (100 mg/mL), and 5% FBS (Moregate Biotech, Bulimba QLD, Australia). When the cells reached ~70% confluency, they were maintained in DMEM with 2% FBS containing 5.5 mmol/L D-glucose (normal glucose [NG]) or 30 mmol/L D-glucose (high glucose [HG]). After a 3-day culture, the cells were maintained in serum-free DMEM containing NG or HG. After 24 h, culture media were collected, concentrated 10 times using 10 kD centrifugal filters (Amicom Ultra-15; Nihon Millipore, Tokyo, Japan), and frozen at −80°C until use. We defined these media as NG-IMS media or HG-IMS media.

Primary culture of DRG neurons and evaluation of neurite outgrowth. DRG neuron cultures were prepared from 5-week-old male C57BL/6 mice (Chubu Kagaku Shizai, Nagoya, Japan), as previously described (22). In brief, DRGs were collected, dissociated by collagenase (Wako Pure Chemical, Osaka, Japan), and diluted in a medium consisting of F-12 media, 10 mmol/L glucose, and 30 nmol/L selenium. Isolated DRG neurons were seeded on glass coverslips coated with poly-L-lysine. DRG neurons were cultured with or without 10 nmol/L GLP-1 (7–37) (Bachem Bioscience, Torrance, CA) or exendin-4

(Sigma-Aldrich) (0.1, 1, 10, and 100 nmol/L). To evaluate the effects of GLP-1R agonists on impaired neurite outgrowth under the diabetic condition, DRG neurons were cultured in HG-IMS media that was diluted one-tenth with F-12 media.

After a 24-h culture, DRG neurons fixed with 4% paraformaldehyde were immunostained with rabbit polyclonal antineurofilament heavy-chain antibody (1:5,000; Nihon Millipore) and visualized with Alexa Fluor 488–coupled goat anti-rabbit IgG antibody (1:200; Invitrogen, Carlsbad, CA). Coverslips were counterstained with 4′,6-Diamidine-2′-phenylindole dihydrochloride (Merck, Tokyo, Japan). Images were captured by a charge-coupled device camera (DP70; Olympus Optical, Tokyo, Japan) using a fluorescence microscope (BX51; Olympus Optical). Neurite outgrowth was observed in 10–20 neurons per coverslip and evaluated by a computed image analysis system (Angiogenesis Image Analyzer version 2; KURABO Industries, Osaka, Japan).

Animals and induction of diabetes. Five-week-old male C57BL/6 mice (Chubu Kagaku Shizai) were used. Diabetes was induced by intraperitoneal injection of streptozotocin (STZ) (150 mg/kg; Sigma-Aldrich). Control mice received an equal volume of citric acid buffer. One week after STZ administration,

evaluated by Western blotting analyses between diabetic and normal mice (DRG: normal mice [n = 4], 1 ± 0.09 and diabetic mice [n = 4], 1.02 ± 0.20, P = 0.875; sciatic nerves: normal mice [n = 4], 1 ± 0.17 and diabetic mice [n = 4], 1.09 ± 1.35, P = 0.438). (A high-quality digital representation of this figure is available in the online issue.)

A

B

FIG. 3. Neurite outgrowth of DRG neurons in IMS media with or without exendin-4 (Ex4). Total length (*A*) and joint number (*B*) of DRG neurons cultured in IMS media were measured. Decreased total length and joint number of DRG neurites cultured in HG were ameliorated by Ex4 in a dose-dependent fashion. Results are means ± SD. ●, Neurite cultured in HG-IMS media; ○, neurite cultured in NG-IMS media. NG-IMS media were obtained from IMS cultured in F-12 media with 5.5 mmol/L D-glucose; HG-IMS media were obtained from IMS cultured in F-12 media with 30 mmol/L D-glucose. **P < 0.005 vs. NG-IMS media without exendin-4; ††P < 0.005 vs. HG-IMS media without exendin-4. n = 10–20. Total length: NG 1,635 ± 1,014 μm per cell and HG 684 ± 410; joint number: NG 79.2 ± 52.5 per cell and HG 24.2 ± 23.8. Total length: HG with 10 nmol/L exendin-4 1,278 ± 457 and HG with 100 nmol/L exendin-4 2,045 ± 1,029. Joint number: HG with 10 nmol/L exendin-4 32.3 ± 12.0 and HG with 100 nmol/L exendin-4 55.1 ± 28.8. Total length: NG with 10 nmol/L exendin-4 1,839 ± 915 and NG with 100 nmol/L exendin-4 1,614 ± 821. Joint number: NG with 10 nmol/L exendin-4 72.7 ± 36.3 and NG with 100 nmol/L exendin-4 49.3 ± 22.3.

the mice with plasma glucose concentrations >16 mmol/L were selected as diabetic mice. Twelve weeks after the induction of diabetes, mice were treated once daily with exendin-4 (10 nmol/kg in 0.1 mL of water i.p.) or vehicle (saline) over 4 weeks (n = 10 in each group). Before and after exendin-4 treatment, fasting blood glucose levels and HbA$_{1c}$ were examined by a FreeStyle Freedom Glucose Meter (Nipro, Osaka, Japan) and a RAPIDIA Auto HbA1c-L assay kit using latex agglutination (Fujirebio, Tokyo, Japan), respectively. After the exendin-4 treatment, intraperitoneal glucose tolerance tests (IPGTTs) were performed on the mice. Serum insulin and glucagon levels also were measured in fasted mice by an insulin ELISA kit (Morinaga Institute of Biological Science, Yokohama, Japan) and a glucagon enzyme immune assay kit (Yanaihara Institute, Fujinomiya, Japan), respectively. The Nagoya University Institutional Animal Care and Use Committee approved the protocols of this experiment.

Measurement of current perception threshold using a neurometer. To determine a nociceptive threshold, the current perception threshold (CPT) was measured in 12- and 16-week diabetic and age-matched normal mice using a CPT/laboratory neurometer (Neurotron, Denver, CO). The electrodes (SRE-0405-8; Neurotron) for stimulation were attached to plantar surfaces. Each mouse was kept in a Ballman cage (Natsume Seisakusho, Tokyo, Japan) suitable

for light restraint to keep awake. Three transcutaneous-sine-wave stimuli with different frequencies (2,000, 250, and 5 Hz) were applied to the plantar surfaces. The intensity of each stimulation was gradually increased automatically (increments of 0.01 mA for 5 and 250 Hz and increments of 0.02 mA for 2,000 Hz). The minimum intensity at which the mouse withdrew its paw was defined as the CPT. Six consecutive measurements were conducted at each frequency.

Nerve conduction velocity. Mice anesthetized with pentobarbital were placed on a heated pad in a room maintained at 25°C to ensure a constant rectal temperature of 37°C. Motor nerve conduction velocity (MNCV) was determined between the sciatic notch and ankle with a Neuropak NEM-3102 instrument (Nihon-Koden, Osaka, Japan), as previously described (5,6,23). The sensory nerve conduction velocity (SNCV) was measured between the knee and ankle with retrograde stimulation.

Sciatic nerve blood flow. Sciatic nerve blood flow (SNBF) was measured by laser-Doppler flowmetry (FLO-N1; Omegawave, Tokyo, Japan). The thigh skin of an anesthetized mouse was cut along the femur and then an incision through the fascia was carefully made to expose the sciatic nerve. Five minutes after this procedure, the blood flow was measured by a laser-Doppler probe placed 1 mm above the nerve. During this measurement, the mouse was placed on a heated pad in a room maintained at 25°C to ensure a constant rectal temperature of 37°C.

Tissue collection. Four weeks after the treatment with exendin-4, mice were killed by an overdose of pentobarbital or perfusion with 50 mL of 4% para-formaldehyde. DRGs and sciatic nerves were obtained from normal and diabetic mice. Some of the tissues were snap frozen in liquid nitrogen, followed by preservation at –80°C until use, and others were transferred to RNAlater solution (Invitrogen), followed by freezing preservation for RT-PCR. For immunohistochemistry, DRGs, pancreas, and sole skin were excised, fixed in 4% paraformaldehyde, and frozen in optimal cutting temperature compound (Sakura Finetechnical, Tokyo, Japan) after cryoprotection.

GLP-1R mRNA expression in DRGs and sciatic nerves. RNAs were extracted from frozen samples of DRGs and sciatic nerves using Isogen (Nippon Gene, Toyama, Japan) and were quantified spectrophotometrically. Starting from 1 μg of RNA, cDNA was synthesized using ReverTra Ace (Toyobo, Osaka, Japan). TaqMan gene expression assays (Applied Biosystems, Foster City, CA) were used for GLP-1R and 18S rRNA for the endogenous control. Real-time quantitative RT-PCR was performed using the Mx3000P QPCR System (Stratagene, La Jolla, CA). Relative quantity was calculated by the $\Delta\Delta C_t$ method with normalization to 18S rRNA (24).

Western blotting. DRGs and sciatic nerves were used for Western blotting. Samples were lysed in detergent lysis buffer (Cell Lysis Buffer; Cell Signaling Technology, Boston, MA) adding 1 mmol/L phenylmethanesulfonylfluoride (Sigma-Aldrich), following centrifugation. Proteins were quantitated the concentrations with a bicinchoninic acid assay (Sigma Chemical) and were transferred to polyvinylidene fluoride membranes (Millipore, Billerica, MA) after SDS-PAGE. Membranes were blocked and incubated with rabbit polyclonal anti–GLP-1R antibody (1:100; Santa Cruz Biotechnology, Santa Cruz, CA) and rabbit polyclonal anti–β-actin antibody (1:10,000; Abcam, Cambridge, MA). Antigen detection was performed using ECL Plus Western Blotting Detection Reagents (Amersham Pharmacia Biotech, Piscataway, NJ) with horseradish peroxidase–conjugated anti-rabbit IgG antibody (1:6,000; Cell Signaling Technology). Images were scanned and their densities were determined by ImageJ (National Institutes of Health, Bethesda, MD). The expression of the GLP-1R protein was corrected by β-actin density, and the expression in tissues of normal mice was arbitrarily set at 1.0.

Immunocytochemistry and frozen section staining. After a 24-h culture, DRG cells, as indicated above, were fixed with 4% paraformaldehyde. The cells were blocked with 3% goat serum, and the following primary antibodies were applied to the glass coverslips at 4°C overnight: rabbit polyclonal anti–GLP-1R antibody (1:200; sc-66911; Santa Cruz Biotechnology); mouse monoclonal anti-neurofilament 70 kDa (NF70) antibody (1:1,000; MAB1615; Millipore); and mouse monoclonal anti-S100b antibody (1:300; S2532; Sigma-Aldrich). After washing, the following secondary antibodies were loaded for 1 h at room temperature in a dark box: Alexa Fluor 488–coupled goat anti-rabbit IgG antibody (1:200; Invitrogen) and Alexa Fluor 594–coupled goat anti-mouse antibody (1:300; Invitrogen).

For immunohistochemistry, after the microwave irradiation in citrate buffer (pH 6.0), cryostat sections were blocked with 5% skim milk (Meiji Milk, Tokyo, Japan) and the following primary antibodies were applied to the sections at 4°C overnight: rabbit polyclonal anti–protein-gene-product 9.5 (PGP 9.5) antibody (1:500; Millipore); guinea-pig polyclonal anti-insulin antibody (1:500, Ab7842-500; Abcam); rabbit polyclonal anti–GLP-1R antibody (1:200, sc-66911, Santa Cruz Biotechnology; LS-A1205 and LS-A1206, MBL International, Woburn, MA); mouse monoclonal NF70 antibody (1:1,000; Millipore); and mouse monoclonal anti-S100b antibody (1:300; Sigma-Aldrich). After washing, the secondary antibodies, as indicated above, were loaded for 1 h at room temperature.

TABLE 1
Body weight, blood glucose, and HbA$_{1c}$ levels in normal and diabetic mice

| | Normal mice | | | Diabetic mice | | |
| | | Posttreatment | | | Posttreatment | |
	Pretreatment	Saline	Exendin-4	Pretreatment	Saline	Exendin-4
n	8	5	6–8	9–10	8	9
Blood glucose (mmol/L)	9.1 ± 1.6	9.1 ± 1.6	8.7 ± 2.4	23.1 ± 2.8*	26.6 ± 2.9*	23.9 ± 2.3*
HbA$_{1c}$ (%)	4.0 ± 0.1	4.1 ± 0.2	3.9 ± 0.1	7.6 ± 1.2*	7.7 ± 2.1*	6.9 ± 2.1*
Body weight (g)	31 ± 3	31 ± 3	27 ± 2†	26 ± 3*	24 ± 4*	23 ± 2*

Data are means ± SD. *$P < 0.05$ vs. pretreatment normal mice. †$P < 0.05$ vs. normal mice treated with saline.

Coverslips and tissues were counterstained with diaminido phenyl indol (Merck). Images were captured by a charge-coupled device camera (DP70; Olympus Optical) using a fluorescence microscope (BX51; Olympus Optical). **Measurement of intraepidermal nerve fiber densities.** Nerve fibers stained with anti–PGP 9.5 antibody were counted as previously reported (25). In brief, each individual nerve fiber with branching inside the epidermis was counted as one, and a nerve fiber with branching in the dermis was counted separately. Six fields from each section were randomly selected for the intraepidermal nerve fiber (IENF) densities (IENFDs). IENFDs were derived and expressed as epidermal nerve fiber numbers per length of the epidermal basement membrane (fibers per millimeter).
Statistical analysis. All the group values were expressed as means ± SD. Statistical analyses were made by one-way ANOVA, with the Bonferroni correction for multiple comparisons. All analyses were performed by personnel who were unaware of the animal identities.

RESULTS

DRG neurons and satellite cells expressed GLP-1Rs. To confirm the quality of GLP-1R antibody, we stained the islets of $glp1r^{-/-}$ mice. GLP-1R antibody obtained from Santa Cruz (sc-66911) detected the β-cells of wild-type mice but not those of $glp1r^{-/-}$ mice. In contrast, GLP-1R antibodies from MBL International (LS-A1205 and LS-A1206) nonspecifically stained the islets of $glp1r^{-/-}$ mice (Supplementary Fig. 1). In addition to immunohistochemistry, GLP-1R protein in the pancreas of wild-type mice was specifically detected and that of $glp1r^{-/-}$ mice was undetected with the GLP-1R antibody from Santa Cruz by Western blotting methods (Supplementary Fig. 2). Therefore, in this study, we used sc-66911 as a primary antibody to detect the expression of GLP-1R in DRGs. GLP-1R expression was detected in both DRG neurons indicated by NF70 and satellite cells indicated by S100b antibody (Fig. 1A–F). In contrast to these wild-type mice DRGs, GLP-1R expression was not detected in the DRGs of $glp1r^{-/-}$ mice (Fig. 1G). To further evaluate the localization of GLP-1R, we stained enzymatically dissociated DRG cells with GLP-1R antibody in addition to S100b or NF70 antibody. GLP-1R proteins also were expressed in both DRG neurons and satellite cells by this immucytochemical method (Supplementary Fig. 3).

GLP-1R agonists promoted neurite outgrowth of DRG neurons. In our DRG culture system, GLP-1R protein was expressed in all neurons and in about two-thirds of glia cells (data not shown). Therefore, we used our DRG culture system to evaluate the impact of the GLP-1R agonist on the sensory nervous system, especially sensory neurons.

Neurite outgrowth of DRG neurons was increased in the presence of GLP-1 (7–37) or exendin-4 (Fig. 2A and B). Total length and joint number of neurites were significantly increased by GLP-1 (7–37) or exendin-4 (joint number: control vs. 10 nmol/L exendin-4, $P = 0.0002$; control vs. 100 nmol/L exendin-4, $P = 0.0093$; and control vs. 10 nmol/L GLP-1 (7–37), $P < 0.0001$; total length: control vs. 10 nmol/L

exendin-4, $P = 0.0003$; control vs. 100 nmol/L exendin-4, $P < 0.0001$; and control vs. 10 nmol/L GLP-1 (7–37), $P < 0.0001$) (Fig. 2C and D).

Exendin-4 ameliorated high glucose–induced reduction in neurite outgrowth of DRG neurons. DRG neurons cultured with HG-IMS media, which mimicked the diabetic state, had shorter neurites and smaller joint numbers compared with those cultured with NG-IMS media, which mimicked the nondiabetic normal state (total length: $P = 0.0205$, joint number: $P = 0.0006$) (Fig. 3). The impaired neurite outgrowth of DRG neurons cultured with HG-IMS media was improved by exendin-4 (total length: HG with 10 nmol/L exendin-4, $P = 0.1620$, and HG with 100 nmol/L exendin-4, $P = 0.0012$; joint number: HG with 10 nmol/L exendin-4, $P = 0.5871$, and HG with 100 nmol/L exendin-4, $P = 0.0433$). In contrast, exendin-4 did not promote the neurite outgrowth of DRG neurons cultured with NG-IMS media.

Levels of GLP-1R in DRGs and sciatic nerves were not impaired in diabetic mice. To ascertain the levels of $glp1r$ mRNA and protein, we carried out real-time PCR analyses and Western blotting analyses in the DRGs and sciatic nerves of normal and diabetic mice before the exendin-4 treatment. The levels of $glp1r$ transcript in DRGs and sciatic nerves of diabetic mice were not significantly different between those of normal mice (DRG: $P = 0.544$, sciatic nerves: $P = 0.606$) (Fig. 1H). Furthermore, there were no significant differences in GLP-1R protein contents between diabetic and normal mice (DRG: $P = 0.875$, sciatic nerves: $P = 0.438$) (Fig. 1I).

Body weights, blood glucose levels, and HbA$_{1c}$. At 12 weeks, diabetic mice showed severe hyperglycemia ($P = 0.0003$) and significantly reduced body weight gain ($P = 0.003$). Random blood glucose levels measured during the experimental period were not significantly different in any group. Exendin-4 treatment for 4 weeks did not alter body weight, blood glucose, or HbA$_{1c}$ levels in the diabetic groups (Table 1).

Serum insulin and glucagon levels and IPGTTs. After the exendin-4 treatment, serum insulin levels were significantly decreased in diabetic mice, and exendin-4 administration provided no significant improvement in both diabetic and normal mice (Supplementary Fig. 4A). In IPGTT, blood glucose levels in diabetic mice after 15 min of glucose injection were significantly elevated compared with those in normal mice. These elevations were not significantly decreased by exendin-4 treatment (Supplementary Fig. 4C).

Although serum glucagon concentrations were not incremented in diabetic mice compared with those in normal mice, the concentrations in diabetic mice had a high propensity to be decreased by exendin-4 treatment (Supplementary Fig. 4B).

- 368 -

Reduced sensory perception in diabetic mice was ameliorated by exendin-4 administration. After 12 weeks of diabetes, CPTs at 5, 250, and 2,000 Hz were significantly increased compared with those in normal mice (5 Hz: $P = 0.015$, 250 Hz: $P = 0.019$, and 2,000 Hz: $P = 0.028$), representing hypoalgesia in diabetic mice. After the 4 weeks of exendin-4 administration, these deficits in sensation were significantly improved in diabetic mice compared with saline-treated diabetic controls (5 Hz: $P = 0.0161$, 250 Hz: $P = 0.0012$, and 2,000 Hz: $P = 0.0011$). The injection of exendin-4 into normal mice did not induce significant changes in CPTs (Fig. 4A–C).

Exendin-4 improved delayed NCVs in diabetic mice. MNCVs and SNCVs of diabetic mice were significantly delayed compared with those of normal mice (MNCV: $P = 0.0341$, SNCV: $P = 0.0489$). The delay in MNCVs and SNCVs was significantly restored by exendin-4 treatment (MNCV: $P = 0.0289$, SNCV: $P = 0.0201$) (Fig. 5A and B). However, exendin-4 administration did not alter NCVs in normal mice.

Nerve fibers in epidermis were preserved by exendin-4. IENFDs were evident in both the epidermis and the dermis of the foot skin by the fluorescent imaging (Fig. 6A). Although IENFDs were decreased in diabetic mice ($P = 0.0011$), this decrement was significantly ameliorated by exendin-4 ($P = 0.0007$) (Fig. 6B). Administration of exendin-4 did not change IENFDs in normal mice ($P = 0.2212$).

Exendin-4 had no effects on SNBF. SNBF in diabetic mice was significantly decreased compared with those in normal mice ($P = 0.0203$), and the decrease was not ameliorated by exendin-4 ($P = 0.7407$) (Fig. 7).

DISCUSSION

In this study, we investigated whether GLP-1R agonists have therapeutic effects on DPN. First, we confirmed the expression of the GLP-1R on DRG neurons by immunohistochemical analyses. Second, we observed that both GLP-1 (7–37) and exendin-4 promoted neurite outgrowth of DRG neurons, and exendin-4 ameliorated the impaired neurite outgrowth of DRG neurons in conditioned media obtained from Schwann cell cultures under high-glucose conditions. We then demonstrated that administration of exendin-4 improved the reduced sensory perception of the plantar pedis, delayed NCVs of hindlimbs, and decreased IENFDs of the plantar skin in diabetic mice. However, neither the hyperglycemic state nor decreased SNBF were improved by exendin-4. These results indicate that exendin-4 has direct effects on peripheral nerves that are independent of its antihyperglycemic and hemodynamic effects.

Several antibodies against the GLP-1R are commercially available. GLP-1R antibodies, LS-A1205 and LS-A1206, produced by MBL International, have recently been used in some studies (26–28). To confirm the reliability of these antibodies, we stained islet cells in which the presence of the GLP-1R has repeatedly been demonstrated (29,30). LS-A1205 and LS-A1206 distinctively reacted with β-cells that also were clearly stained with anti-insulin antibody, but these antisera also reacted with β-cells or perhaps α-cells in $Glp1r^{-/-}$ mice. We then tested another antibody for GLP-1R, sc-66911 (Santa Cruz). This antiserum detected β-cells

FIG. 4. Evaluation of sensory nerve functions. Measurements of CPTs at 2,000 (A), 250 (B), and 5 (C) Hz by a neurometer were performed before and at the end of exendin-4 (Ex4) administration. CPTs for all pulses were significantly increased in the diabetic group (DM), and these deficits were significantly prevented by exendin-4. N, normal mice; S, saline. Results are means ± SD. #$P < 0.05$ vs. pretreatment

normal mice; *$P < 0.05$ vs. saline-treated normal mice; †$P < 0.05$ vs. saline-treated diabetic mice. Saline-treated normal mice, $n = 8$; exendin-4–treated normal mice, $n = 8$; saline-treated diabetic mice, $n = 9$; exendin-4–treated diabetic mice, $n = 9$.

FIG. 5. NCVs. MNCV (*A*) and SNCV (*B*) were measured before and after the treatment with exendin-4 (Ex4). DM, diabetic mice; N, normal mice; S, saline. Before the treatment: MNCV for normal mice 45.2 ± 2.7 m/s and diabetic mice 37.5 ± 8.2, *P* = 0.0341; SNCV for normal mice 33.0 ± 4.6 and diabetic mice 28.6 ± 7.2, *P* = 0.0489. After the treatment: MNCV for saline-treated diabetic mice 34.5 ± 8.1 and exendin-4–treated diabetic mice 43.3 ± 7.9, *P* = 0.0289; SNCV for saline-treated diabetic mice 28.6 ± 5.6 and exendin-4–treated diabetic mice 38.0 ± 8.5, *P* = 0.0201. Results are means ± SD. #*P* < 0.05 vs. pretreatment normal mice. *P < 0.05 vs. saline-treated normal mice. †*P* < 0.05 vs. saline-treated diabetic mice. Saline-treated normal mice, *n* = 7; exendin-4–treated normal mice, *n* = 8; saline-treated diabetic mice, *n* = 8; exendin-4–treated diabetic mice, *n* = 8.

of wild-type mice but did not react with those of $glp1r^{-/-}$ mice (Supplementary Fig. 1). Furthermore, the antiserum detected GLP-1R proteins in the pancreata of wild-type mice but not in that of $glp1r^{-/-}$ mice, using immunoblotting assay. We confirmed the expression of GLP-1R in DRG neurons and glia cells with a GLP-1R antibody, sc-66911.

GLP-1 and exendin-4 previously have been shown to promote neurite outgrowth of rat pheochromocytoma cells (19,31) and to protect rat primary hippocampal neurons from cell death (14). It has been reported that exogenous GLP-1R activation significantly reduces glucose-dependent reactive oxygen species generation in hypothalamus (32). These antioxidative effects of GLP-1R agonists might yield benefits to central and peripheral nervous systems.

The dipeptidyl peptidase (DPP)-IV inhibitor (vildagliptin) recently has been shown to prevent peripheral nerve degeneration in STZ-induced diabetic mice (33). Although GLP-1 is one of the substrates of DPP-IV, several bioactive peptides, such as neuropeptide Y, substance P, glucagon-like peptide-2, and stromal cell–derived factor-1α also have been reported as substrates of DPP-IV (34,35). Among these peptides, neuropeptide Y and substance P are known as neurotransmitters or modulators of peripheral nervous systems (36,37), and it also has been demonstrated that stromal cell–derived factor-1α released from DRG glia regulates leukocyte chemotaxis and modulates neuropathic pain behavior (38). Therefore, the preventive effects of the DPP-IV inhibitor on DPN may be attributed to its protective effects on these neurotrophic peptides and mediated through increased levels of GLP-1.

Although we cannot infer the precise site(s) of action of exendin-4 in our diabetic mice that ameliorated DPN in vivo, our data using cellular models of DPN in vitro implicate a direct role for GLP-1 and the GLP-1R agonist exendin-4. We previously reported that conditioned media obtained from Schwann cell cultures under high-glucose conditions

impaired neurite outgrowth of DRG neurons, likely mediated through a decrease in nerve growth factor production (21). In our current study, the impaired neurite outgrowth induced by hyperglycemia-conditioned IMS media was improved by exendin-4. In contrast, under the normal glucose–conditioned IMS media, which mimicked the nondiabetic normal state, exendin-4 did not exert any changes in neurite outgrowth because of basal enhancement of neurite outgrowth by various growth factors, such as nerve growth factor secreted from Schwann cells (21). These results indicate that GLP-1R agonists exert regenerative effects on peripheral sensory neurons under experimental conditions, mimicking diabetes in vitro. Additional studies on the effect on the role of downstream neurotrophic factors, such as nerve growth factor, will be required to evaluate the mechanism of action of GLP-1R agonists.

We also demonstrated the effects of exendin-4 on DPN in STZ-induced diabetic mice. We evaluated sensory nerve functions using a CPT/laboratory neurometer. The neurometer is now widely and clinically used to evaluate the effects of analgesic drugs and peripheral nerve functions in various painful neuropathies, including DPN (39–42). In this study, after 12 weeks of diabetes, hypoalgesia at 2,000, 250, and 5 Hz was observed in the diabetic mice, and injection of exendin-4 improved these abnormalities. In addition, exendin-4 ameliorated the decreased IENFDs in diabetic mice. The restoration of sensory functions by exendin-4 was confirmed by the improvement of IENFDs.

In addition, we measured MNCVs and SNCVs that represent relatively large axonal functions. Both the delayed MNCVs and SNCVs in diabetic mice were improved by exendin-4, indicating that exendin-4 had therapeutic effects on impaired motor and sensory nerve functions. These data also are consistent with previous reports (14,16,18,19) that revealed the plausible effects of GLP-1 or GLP-1R agonists on central and peripheral nerve disorders.

FIG. 6. IENFDs after the treatment with exendin-4 (Ex4). *A*: IENFs indicated by white arrowheads were detected by immunofluorescence assay with anti–PGP 9.5 antibody (red). *B*: Quantification of the density revealed a significant decrement in untreated diabetic mice and the significant amelioration by exendin-4 treatment. DM, diabetic mice; N, normal mice; S, saline. Bar: 20 μm. Saline-treated normal mice 38.5 ± 3.9, saline-treated diabetic mice 27.7 ± 1.9, exendin-4–treated normal mice 42.1 ± 2.4, and exendin-4–treated diabetic mice 40.2 ± 3.1 fibers per mm. Results are means ± SD. #$P < 0.05$ vs. pretreatment normal mice. *$P < 0.05$ vs. saline-treated normal mice. †$P < 0.05$ vs. saline-treated diabetic mice. Saline-treated normal mice, $n = 4$; exendin-4–treated normal mice, $n = 3$; saline-treated diabetic mice, $n = 4$; exendin-4–treated diabetic mice, $n = 3$. (A high-quality digital representation of this figure is available in the online issue.)

FIG. 7. SNBF treated with or without exendin-4 (Ex4) in normal (N) or diabetic (DM) mice. S, saline. Saline-treated normal mice 19.4 ± 2.4, saline-treated diabetic mice 14.4 ± 3.6, and exendin-4–treated diabetic mice 15.2 ± 5.2 mL/min/100 g. Results are means ± SD. *$P < 0.05$ vs. saline-treated normal mice. Saline-treated normal mice, $n = 9$; exendin-4–treated normal mice, $n = 8$; saline-treated diabetic mice, $n = 8$; exendin-4–treated diabetic mice, $n = 9$.

Decreased nerve blood flow has been recognized as one of the most important mechanisms in the development of DPN. Recently, GLP-1R has been detected in blood vessels, and the beneficial effects of GLP-1 or GLP-1R agonists on vascular functions have been reported (28,43,44). In our experimental study, however, exendin-4 did not alter normal nerve blood flow in normal mice nor did it improve the reduced nerve blood flow in diabetic mice. One of the reasons for this discrepancy is that the vasodilatory actions of GLP-1 agonists are likely mediated mainly through a GLP-1R–independent pathway, which depends on a GLP-1 metabolite, GLP-1 (9–36) (28). In our present study, therefore, exendin-4 could not exert vasoregulatory effects. Another reason is that the central-peripheral sympathetic nervous system function would likely be impaired in the diabetic state. It has been reported that GLP-1 in the central nervous system regulates sympathetic outflow, resulting in increases in blood pressure and heart rate independent of the peripheral actions of GLP-1 on glucoregulation (43,44). As mice with a long duration of diabetes in the current study might have developed sympathetic nerve dysfunction, exendin-4 may have been unable to modulate nerve blood flow after prolonged experimental diabetes. Although the precise mechanisms remain unclear, the effects of exendin-4 on DPN may be attributed to its direct actions on DRG neurons and their axons.

Because GLP-1R agonists possess glucose-lowering effects, we used a dosing regimen that did not produce sustained reductions in blood glucose or body weight. Although trends toward reduced levels of HbA$_{1c}$ and glucagon were observed in exendin-4–treated diabetic mice (Table 1 and Supplementary Fig. 4), there were no significant differences in the glucose levels, insulin concentrations, or IPGTTs between exendin-4–treated and untreated mice. In previous studies (45,46), exendin-4 was administrated at the same time as or before STZ injection. On the other hand, we started exendin-4 injections 12 weeks after the onset of diabetes. Because HbA$_{1c}$ in diabetic mice treated with exendin-4 tended to decrease (Table 1), longer treatment or larger doses of exendin-4 might have significantly improved hyperglycemia, indirectly contributing to the amelioration of DPN. In the current study, however, it is conceivable that the effectiveness of exendin-4 on DPN may be independent of the glucose-lowering effects.

Miki et al. (47) previously reported that glucose-responsive neurons in the hypothalamus regulate the secretion of glucagon and govern the glucose homeostasis. In addition, it was shown in a recent study that GLP-1R agonists had a glucagon-lowering effect (48), which is consistent with the present observation that glucagon concentrations tended to be decreased by the administration of exendin-4 in diabetic mice. It remains to be evaluated whether the glucagon levels influence the pathophysiology of DPN through mechanisms independent of hyperglycemia.

In conclusion, we demonstrated the beneficial effects of GLP-1R agonist on DPN. GLP-1 analogs and GLP-1R

- 371 -

agonists have been broadly used as antihyperglycemic agents in type 2 diabetic patients. In addition to the established use of these agents to control blood glucose, there currently is little data demonstrating an effect of GLP-1R agonists on peripheral nerve functions. Our data demonstrating the improvement of experimental DPN after administration of GLP-1 and exendin-4 suggest that additional clinical investigation with attention to whether therapy with GLP-1R agonists produce changes in DPN may be warranted.

REFERENCES

1. Toth C, Brussee V, Cheng C, Zochodne DW. Diabetes mellitus and the sensory neuron. J Neuropathol Exp Neurol 2004;63:561–573
2. Zochodne DW. Diabetes mellitus and the peripheral nervous system: manifestations and mechanisms. Muscle Nerve 2007;36:144–166
3. Kles KA, Vinik AI. Pathophysiology and treatment of diabetic peripheral neuropathy: the case for diabetic neurovascular function as an essential component. Curr Diabetes Rev 2006;2:131–145
4. Genuth S. Insights from the diabetes control and complications trial/epidemiology of diabetes interventions and complications study on the use of intensive glycemic treatment to reduce the risk of complications of type 1 diabetes. Endocr Pract 2006;12(Suppl. 1):34–41
5. Nakae M, Kamiya H, Naruse K, et al. Effects of basic fibroblast growth factor on experimental diabetic neuropathy in rats. Diabetes 2006;55:1470–1477
6. Naruse K, Hamada Y, Nakashima E, et al. Therapeutic neovascularization using cord blood-derived endothelial progenitor cells for diabetic neuropathy. Diabetes 2005;54:1823–1828
7. Shibata T, Naruse K, Kamiya H, et al. Transplantation of bone marrow-derived mesenchymal stem cells improves diabetic polyneuropathy in rats. Diabetes 2008;57:3099–3107
8. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006;368:1696–1705
9. Lovshin JA, Drucker DJ. Incretin-based therapies for type 2 diabetes mellitus. Nat Rev Endocrinol 2009;5:262–269
10. Gutniak M, Orskov C, Holst JJ, Ahrén B, Efendic S. Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus. N Engl J Med 1992;326:1316–1322
11. Dupre J, Behme MT, Hramiak IM, et al. Glucagon-like peptide I reduces postprandial glycemic excursions in IDDM. Diabetes 1995;44:626–630
12. Turton MD, O'Shea D, Gunn I, et al. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 1996;379:69–72
13. Hansotia T, Maida A, Flock G, et al. Extrapancreatic incretin receptors modulate glucose homeostasis, body weight, and energy expenditure. J Clin Invest 2007;117:143–152
14. Perry T, Lahiri DK, Sambamurti K, et al. Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (Abeta) levels and protects hippocampal neurons from death induced by Abeta and iron. J Neurosci Res 2003;72:603–612
15. During MJ, Cao L, Zuzga DS, et al. Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nat Med 2003;9:1173–1179
16. Bertilsson G, Patrone C, Zachrisson O, et al. Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of Parkinson's disease. J Neurosci Res 2008;86:326–338
17. Belsham DD, Fick LJ, Dalvi PS, et al. Ciliary neurotrophic factor recruitment of glucagon-like peptide-1 mediates neurogenesis, allowing immortalization of adult murine hypothalamic neurons. FASEB J 2009;23:4256–4265
18. Li Y, Perry T, Kindy MS, et al. GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism. Proc Natl Acad Sci USA 2009;106:1285–1290
19. Perry T, Lahiri DK, Chen D, et al. A novel neurotrophic property of glucagon-like peptide 1: a promoter of nerve growth factor-mediated differentiation in PC12 cells. J Pharmacol Exp Ther 2002;300:958–966
20. Perry T, Holloway HW, Weerasuriya A, et al. Evidence of GLP-1-mediated neuroprotection in an animal model of pyridoxine-induced peripheral sensory neuropathy. Exp Neurol 2007;203:293–301
21. Watabe K, Fukuda T, Tanaka J, Honda H, Toyohara K, Sakai O. Spontaneously immortalized adult mouse Schwann cells secrete autocrine and paracrine growth-promoting activities. J Neurosci Res 1995;41:279–290
22. Tosaki T, Kamiya H, Yasuda Y, et al. Reduced NGF secretion by Schwann cells under the high glucose condition decreases neurite outgrowth of DRG neurons. Exp Neurol 2008;213:381–387
23. Nakamura J, Kato K, Hamada Y, et al. A protein kinase C-β–selective inhibitor ameliorates neural dysfunction in streptozotocin-induced diabetic rats. Diabetes 1999;48:2090–2095
24. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001;25:402–408
25. Beiswenger KK, Calcutt NA, Mizisin AP. Epidermal nerve fiber quantification in the assessment of diabetic neuropathy. Acta Histochem 2008;110:351–362
26. Arakawa M, Mita T, Azuma K, et al. Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4. Diabetes 2010;59:1030–1037
27. Tornehave D, Kristensen P, Rømer J, Knudsen LB, Heller RS. Expression of the GLP-1 receptor in mouse, rat, and human pancreas. J Histochem Cytochem 2008;56:841–851
28. Ban K, Noyan-Ashraf MH, Hoefer J, Bolz SS, Drucker DJ, Husain M. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation 2008;117:2340–2350
29. Thorens B. Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1. Proc Natl Acad Sci USA 1992;89:8641–8645
30. Montrose-Rafizadeh C, Avdonin P, Garant MJ, et al. Pancreatic glucagon-like peptide-1 receptor couples to multiple G proteins and activates mitogen-activated protein kinase pathways in Chinese hamster ovary cells. Endocrinology 1999;140:1132–1140
31. Kimura R, Okouchi M, Fujioka H, et al. Glucagon-like peptide-1 (GLP-1) protects against methylglyoxal-induced PC12 cell apoptosis through the PI3K/Akt/mTOR/GCLc/redox signaling pathway. Neuroscience 2009;162:1212–1219
32. Cabou C, Campistron G, Marsollier N, et al. Brain glucagon-like peptide-1 regulates arterial blood flow, heart rate, and insulin sensitivity. Diabetes 2008;57:2577–2587
33. Jin HY, Liu WJ, Park JH, Baek HS, Park TS. Effect of dipeptidyl peptidase-IV (DPP-IV) inhibitor (Vildagliptin) on peripheral nerves in streptozotocin-induced diabetic rats. Arch Med Res 2009;40:536–544
34. Mentlein R. Dipeptidyl-peptidase IV (CD26): role in the inactivation of regulatory peptides. Regul Pept 1999;85:9–24
35. De Meester I, Durinx C, Bal G, et al. Natural substrates of dipeptidyl peptidase IV. Adv Exp Med Biol 2000;477:67–87
36. Allen BJ, Rogers SD, Ghilardi JR, et al. Noxious cutaneous thermal stimuli induce a graded release of endogenous substance P in the spinal cord: imaging peptide action in vivo. J Neurosci 1997;17:5921–5927
37. Ji RR, Zhang X, Wiesenfeld-Hallin Z, Hökfelt T. Expression of neuropeptide Y and neuropeptide Y (Y1) receptor mRNA in rat spinal cord and dorsal root ganglia following peripheral tissue inflammation. J Neurosci 1994;14:6423–6434
38. White FA, Jung H, Miller RJ. Chemokines and the pathophysiology of neuropathic pain. Proc Natl Acad Sci USA 2007;104:20151–20158

39. Katims JJ, Naviasky EH, Ng LK, Rendell M, Bleecker ML. New screening device for assessment of peripheral neuropathy. J Occup Med 1986;28: 1219–1221
40. Masson EA, Veves A, Fernando D, Boulton AJ. Current perception thresholds: a new, quick, and reproducible method for the assessment of peripheral neuropathy in diabetes mellitus. Diabetologia 1989;32:724–728
41. Veves A, Young MJ, Manes C, Boulton AJ. Differences in peripheral and autonomic nerve function measurements in painful and painless neuropathy: a clinical study. Diabetes Care 1994;17:1200–1202
42. Matsutomo R, Takebayashi K, Aso Y. Assessment of peripheral neuropathy using measurement of the current perception threshold with the neurometer in patients with type 2 diabetes mellitus. J Int Med Res 2005;33:442–453
43. Yamamoto H, Lee CE, Marcus JN, et al. Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons. J Clin Invest 2002;110:43–52
44. Barragán JM, Eng J, Rodríguez R, Blázquez E. Neural contribution to the effect of glucagon-like peptide-1-(7-36) amide on arterial blood pressure in rats. Am J Physiol 1999;277:E784–E791
45. Li Y, Hansotia T, Yusta B, Ris F, Halban PA, Drucker DJ. Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis. J Biol Chem 2003;278:471–478
46. Maida A, Hansotia T, Longuet C, Seino Y, Drucker DJ. Differential importance of glucose-dependent insulinotropic polypeptide vs glucagon-like peptide 1 receptor signaling for beta cell survival in mice. Gastroenterology 2009;137:2146–2157
47. Miki T, Liss B, Minami K, et al. ATP-sensitive K+ channels in the hypothalamus are essential for the maintenance of glucose homeostasis. Nat Neurosci 2001;4:507–512
48. Burcelin R, Knauf C, Cani PD. Pancreatic alpha-cell dysfunction in diabetes. Diabetes Metab 2008;34(Suppl. 2):S49–S55

- 373 -

Impact of endogenous and exogenous insulin on basal energy expenditure in patients with type 2 diabetes under standard treatment[1–3]

Kaori Ikeda, Shimpei Fujimoto, Masashi Goto, Chizumi Yamada, Akihiro Hamasaki, Kenichiro Shide, Takashi Kawamura, and Nobuya Inagaki

ABSTRACT

Background: Factors that affect resting energy expenditure or basal energy expenditure (BEE) in patients with type 2 diabetes under standard treatment have not been evaluated in detail.

Objective: We determined the clinical factors that affected BEE in addition to body composition in patients with type 2 diabetes under standard treatment.

Design: BEE was measured by using indirect calorimetry under a strict basal condition in 58 Japanese patients with type 2 diabetes after >7 d as inpatients under management of diabetes with medical nutrition therapy and medications. Insulin secretion was measured with a glucagon test. Stepwise regression was applied to explore determinants of BEE.

Results: In the stepwise estimation, insulin secretion ($P = 0.015$), insulin therapy ($P = 0.012$), and pulse rate ($P = 0.011$) were selected in addition to fat-free mass (FFM) ($P < 0.001$) and fat mass ($P = 0.006$) as significant independent determinants of BEE. Standardized partial regression coefficients of the additional 3 factors were -0.16, -0.15, and 0.15, respectively, whereas those for FFM and fat mass were 0.82 and 0.19, respectively. The additional 3 factors explained another 3.9% of the variability of BEE, and the adjusted coefficient of determination was 83.4%. Age, sex, other medications, and parameters of glycemic control were not significant determinants beyond the combined contribution of body composition, endogenous and exogenous insulin, and pulse rate.

Conclusion: Endogenous insulin secretion and exogenous insulin administered in treatment have significant independent effects in the lowering of BEE in patients with diabetes under standard management with medical nutrition therapy and medications. *Am J Clin Nutr* 2011;94:1513–8.

INTRODUCTION

MNT[4] is the basis and starting point of treatment of all patients with diabetes, and the failure of MNT alone may predict the inability to attain optimal glycemic control. In addition, in obese patients with diabetes, MNT aims at weight control to improve insulin resistance and avoid obesity-related health problems. Therefore, estimation of the daily energy expenditure of patients is necessary for individualized diabetic meal plans. For example, MNT for obese patients provides a diet of 500–1000 kcal less energy than the estimated energy expenditure (1). REE or BEE is defined as the minimal amount of energy expended to maintain metabolic activities of cells, tissues, and organs and represents a large component of daily energy expenditure. REE or BEE is used to estimate total energy expenditure as a multiple of REE or BEE according to daily activity.

In healthy subjects, 65–90% of the interindividual variation in REE is explained by FFM or high-metabolic-rate organ mass (2, 3). In patients with diabetes, FFM is also assumed to be a main factor that affects REE and BEE. The influence of the diabetic condition on energy expenditure has also been examined. After adjustment for FFM, REE and BEE in patients with diabetes were shown to be greater than those in healthy control (4, 5). In contrast, no difference was reported in FFM-adjusted REE between mildly hyperglycemic patients and control subjects (6). In addition, a treatment-induced reduction of REE has been reported in type 1 and type 2 diabetes (7, 8). However, the factors that affect REE or BEE in patients with diabetes under standard treatment, which are the more important in clinical practice, have not been precisely evaluated.

In most studies that evaluated energy expenditure, REE has been measured rather than BEE. However, resting conditions are defined less rigorously than are basal conditions, and REE can include components that involve physical or psychological stress and variations in ambient and body temperature (9–11). BEE is measured early in the morning before the subject has engaged in any physical activity and ≥ 10 h after ingestion of any food, drink, or nicotine and remains remarkably constant on a daily basis (9, 11). We applied the measurement of BEE under such

strict basal conditions to minimize the interindividual variation derived from methodologic or external unknown factors.

In the current study, clinical factors that might affect BEE in patients with diabetes under standard treatment were evaluated.

SUBJECTS AND METHODS

Subjects

Japanese patients with type 2 diabetes who were admitted to the Department of Diabetes and Clinical Nutrition, Kyoto University Hospital, Kyoto, Japan, for diabetes self-management education during the period of December 2007 through September 2009 were recruited. The study protocol was approved by the ethics committee of Kyoto University. Written informed consent was obtained from all participants.

During admission, which averaged ~18 d, participants took MNT with or without medications, including oral hypoglycemic agents and insulin, according to the treatment guide for diabetes of the Japan Diabetes Society (12). The physical activity of subjects was not restricted, but participants did not engage in intensive exercise. Participants were screened by a medical history, physical examination, and laboratory examination to ensure the absence of hepatic, renal (including macroalbuminurea), pulmonary, thyroid, and cardiac dysfunction, inflammation, and malignant tumors. Participants who took steroids or β-blockers and subjects who had physical disabilities were excluded.

Energy expenditure

BEE was measured in the morning >7 d after admission under glycemic control with MNT (29.0 ± 2.6 kcal/kg of standard body weight/d that consisted of 52% carbohydrate, 20% protein, and 28% fat in energy-intake percentages) and with without prescribed medications. Standard body weight (in kg) was calculated by multiplying 22 (kg/m^2) by square of height (in m). Premenopausal women were studied during their follicular phase within 7 d after the last day of menstruation.

Whole-body oxygen consumption and carbon dioxide production were measured for >10 min with indirect calorimetry (AE300S; Minato Medical Science) by one investigator at the bedside of each participant under the strict condition of the methods described previously (9, 10, 13). Briefly, afebrile patients in a postabsorptive state after an overnight fast (14 h) with <10 mmol capillary PG/L before the measurement remained in a supine position after waking on the bed in the ward without smoking or taking caffeine, and measurements were performed at room temperature between 22°C and 27°C. After discarding the initial 5 min of data, we adopted 5 consecutive minutes of data from the rest in accord with the steady state definition (10) during which the CV for oxygen consumption and carbon dioxide production was achieved at ≤10% and applied them to the Weir formula together with 24-h urinary urea nitrogen (14).

Body composition

Height was measured on the day of admission, and body weight was measured immediately after measurement of BEE. FFM and fat mass were measured with a dual energy X-ray absorptiometry scanner (Discovery; Hologic) within 3 d before or after the measurement of BEE.

Clinical and metabolic factors

The duration of diabetes was determined from medical records, medical histories, and previous clinical data according to the criteria for the diagnosis of diabetes proposed by the American Diabetes Association (15). Hb A_{1c} was measured by using HPLC (ADAMS A1C HA8180; Arcray) and expressed as a National Glycohemoglobin Standardization Program equivalent value (A_{1c}; percentage) calculated by the formula

$$\text{Percentage of } A_{1c} = \text{percentage of Hb } A_{1c}$$
$$\text{(Japan Diabetes Society)} + 0.4\% \quad (1)$$

which considers the relational expression of Hb A_{1c} (Japan Diabetes Society) (percentage) measured by using the previous Japanese standard substance and measurement methods and Hb A_{1c} (National Glycohemoglobin Standardization Program) (16). Thyroid stimulating hormone was measured by using electrochemiluminescence immunoassay (Elecsys Anti-Tg; Roche Diagnostics GmbH) to confirm the absence of thyroid dysfunction. Capillary glucose before each meal was measured with a glucose meter (One Touch Ultra; Johnson & Johnson) and expressed as capillary PG. As a variable of glycemic control, the mean preprandial PG for 3 consecutive days before the measurement of BEE and FPG just before the measurement of BEE was used. The mean pulse rate was calculated from the records of checkups by nurses on 3 consecutive days including the day of BEE measurement.

Insulin secretion

β cell function was evaluated after an overnight fast by measuring CPR6' (17) because the test is valid in patients who take insulin therapy. The serum C-peptide immunoreactivity was measured by using an immunoenzymometric assay (ST AIA-PACK C-peptide; Toso). On the morning of the glucagon test, participants took their medication after the test.

Statistical analysis

Descriptive data were expressed as means ± SDs. Information of medications, including insulin, sulfonylurea, and metformin, was coded as use = 1 and nonuse = 0. Sex was coded as male = 1 and female = 0. The Mann-Whitney U and Fisher's exact tests were performed to identify differences in the characteristics of men and women. The interrelation between BEE and clinical factors was investigated by means of Kendall's rank correlation coefficients. Clinical factors include body composition (FFM and fat mass), FPG, mean preprandial PG, A_{1c}, insulin secretion, mean pulse rate, dietary energy, and medications (ie, insulin, sulfonylurea, and metformin). A multiple linear regression analysis was performed to evaluate the contribution of each determinant to BEE. Variables were selected by stepwise estimation from age, sex, and the clinical factors previously described. When P was <0.05 and ≥0.15, the variable was added and removed, respectively. Data were analyzed by use of Stata 11.0 software (StataCorp). Statistical significance was set at $P < 0.05$ (2-tailed).

TABLE 1
Characteristics of participants[1]

	All	Men	Women
Patients (n)	58	35	23
Age (y)[2]	60.2 ± 9.2[3]	57.6 ± 9.7	64.0 ± 7.1
Body weight (kg)[2]	63.7 ± 15.6	68.3 ± 16.5	56.8 ± 11.2
BMI (kg/m[2])	24.2 ± 5.0	24.1 ± 5.6	24.4 ± 4.1
FFM (kg)[2]	48.4 ± 11.1	54.1 ± 9.4	39.7 ± 7.1
BEE (kcal/d)[2]	1294 ± 227	1397 ± 217	1136 ± 135
CPR6' (ng/mL)	3.4 ± 1.8	3.4 ± 2.0	3.3 ± 1.6
FPG (mg/dL)	114.5 ± 25.2	113.7 ± 25.1	115.6 ± 25.9
PPPG (mg/dL)	143.9 ± 35.5	147.5 ± 37.6	138.5 ± 32.0
A_{1c} (%)	10.5 ± 2.5	10.3 ± 2.4	10.9 ± 2.7
Pulse rate (beats/min)	72.7 ± 10.1	75.0 ± 10.8	69.2 ± 7.8
Duration of diabetes (y)	8.4 ± 7.0	10.0 ± 7.9	5.9 ± 4.4
Treatment			
Diet (kcal $\cdot$ SBW$^{-1} \cdot$ d^{-1})	28.8 ± 2.4	28.7 ± 2.0	29.0 ± 3.0
Medications (n)			
Insulin only	24	17	7
Insulin + metformin	10	4	6
Insulin + sulfonylurea	3	2	1
Insulin + sulfonylurea + metformin	1	0	1
Sulfonylurea only	8	5	3
Sulfonylurea + metformin	5	2	3
Metformin only	4	3	1
None	3	2	1

[1] A_{1c}, glycohemoglobin; BEE, basal energy expenditure; CPR6', C-peptide immunoreactivity 6 min after intravenous glucagon injection; FFM, fat-free mass; FPG, fasting plasma glucose just before the measurement of BEE; PPPG, mean preprandial plasma glucose for 3 consecutive days before the measurement of BEE; SBW, standard body weight.
[2] Mann-Whitney U test revealed significant ($P < 0.05$) differences between men and women.
[3] Mean $\pm$ SD (all such data).

RESULTS

Participant characteristics and results of measurement are shown in **Table 1**. BMI (in kg/m[2]), CPR6', FPG, PPPG, A_{1c}, pulse rate, duration of diabetes, and treatment did not differ significantly between men and women, whereas body weight, FFM, and BEE were significantly higher in men, and age was higher in women.

Significant positive correlations were observed between BEE and FFM ($r = 0.72$) and dietary energy ($r = 0.33$), but dietary energy also had a significant positive correlation with FFM ($r = 0.37$) and a significant negative correlation with fat mass ($r = -0.38$) (**Table 2**). Fat mass had a significant negative correlation with mean preprandial PG ($r = -0.30$) and a significant positive correlation with insulin secretion (CPR6') ($r = 0.43$)

TABLE 2
Correlations between BEE and possible determinants of BEE[1]

	BEE	FFM	FM	FPG	PPPG	A_{1c}	CPR6'	PR	Diet	Insulin[2]	Sulfonylurea[2]
BEE	1.00	—	—	—	—	—	—	—	—	—	—
FFM	0.72*	1.00	—	—	—	—	—	—	—	—	—
FM	0.18[†]	0.16	1.00	—	—	—	—	—	—	—	—
FPG	−0.05	−0.08	−0.13	1.00	—	—	—	—	—	—	—
PPPG	−0.08	−0.08	−0.30*	0.42*	1.00	—	—	—	—	—	—
A_{1c}	−0.07	−0.03	−0.14	0.16	0.18[†]	1.00	—	—	—	—	—
CPR6'	0.19[†]	0.19[†]	0.43*	0.03	−0.23[†]	−0.09	1.00	—	—	—	—
PR	0.21[†]	0.14	0.05	0.07	0.08	−0.06	0.07	1.00	—	—	—
Diet	0.33*	0.37*	−0.38*	0.07	0.20[†]	0.06	−0.14	0.09	1.00	—	—
Insulin[2]	−0.12	−0.06	−0.18	0.28[†]	0.37*	0.27[†]	−0.24[†]	0.13	0.00	1.00	—
Sulfonylurea[2]	0.01	−0.00	0.12	−0.36[‡]	−0.28[†]	−0.11	0.07	−0.15	−0.06	−0.57*	1.00
Metformin[2]	0.18	0.15	0.40*	−0.13	−0.38*	−0.01	0.29[‡]	0.05	−0.22	−0.16	0.01

[1] A_{1c}, glycohemoglobin; BEE, basal energy expenditure (kcal/d); CPR6', C-peptide immunoreactivity 6 min after intravenous glucagon injection (ng/mL); Diet, energy of diet (kcal/d); FFM, fat-free mass (kg); FM, fat mass (kg); FPG, fasting plasma glucose just before the measurement of BEE (mg/dL); PPPG, mean preprandial plasma glucose for 3 consecutive days before the measurement of BEE (mg/dL); PR, pulse rate (beats/min). *[†,‡]Kendall's correlation coefficients ($n = 58$): *$P < 0.001$, [†]$P < 0.05$, [‡]$P < 0.01$.
[2] Use = 1; nonuse = 0.

TABLE 3
Regression models for BEE and body composition and other clinical factors[1]

	Coef (95% CI)	SE	Std coef	P	Adjusted R^2
Model 1					
BEE (FFM + FM)					0.795
Intercept	400.0 (277.1, 523.1)	61.4	—	<0.001	
FFM	17.0 (14.3, 19.7)	1.3	0.83	<0.001	
FM	4.3 (0.3, 8.4)	2.0	0.14	0.038	
Model 2[2]					
BEE (FFM + FM + CPR6' + INS + PR)					0.834
Intercept	256.2 (59.3, 453.0)	98.1	—	0.012	
FFM	16.9 (14.3, 19.4)	1.3	0.82	<0.001	
FM	5.8 (1.8, 9.8)	2.0	0.19	0.006	
CPR6'	−19.9 (−35.6, −4.1)	7.9	−0.16	0.015	
Insulin[2]	−69.9 (−124.0, −15.7)	27.0	−0.15	0.012	
PR	3.3 (0.8, 5.9)	1.3	0.15	0.011	

[1] Model 1 predicted BEE only from body composition by linear regression analysis ($n = 58$). The final regression model (model 2) used independent variables selected from FFM, FM, age, sex, CPR6', fasting plasma glucose, mean preprandial plasma glucose, A_{1c}, dietary energy, use of insulin, use of metformin, use of sulfonylurea, and pulse rate by stepwise estimation ($n = 58$). A_{1c}, glycohemoglobin (%); BEE, basal energy expenditure (kcal/d); Coef, partial regression coefficient; CPR6', C-peptide immunoreactivity 6 min after intravenous glucagon injection (ng/mL); FFM, fat-free mass (kg) measured by using dual energy X-ray absorptiometry; FM, fat mass (kg) measured by using dual energy X-ray absorptiometry (kg); INS, insulin; PR, pulse rate (beats/min); Std coef, standardized coefficient.

[2] Use = 1; nonuse = 0.

and use of metformin ($r = 0.40$). FPG had a negative correlation with the use of sulfonylurea ($r = -0.36$). Mean preprandial PG had a positive correlation with the use of insulin ($r = 0.37$) and a negative correlation with the use of metformin ($r = -0.38$). Insulin secretion (CPR6') had a negative correlation with the use of insulin ($r = -0.24$) and a positive correlation with the use of metformin ($r = 0.29$).

Because clinical factors were naturally correlated with each other, possible spurious correlation and suppressor variables were investigated by means of multiple regression analysis. The model that predicted BEE from body composition alone is shown in **Table 3** (model 1). Another model included selected variables by stepwise estimation (model 2). Insulin secretion (CPR6'; $P = 0.015$), use of insulin ($P = 0.012$) and pulse rate ($P = 0.011$) were significant determinants of BEE in addition to FFM ($P < 0.001$) and fat mass ($P = 0.006$). These additional factors explained another 3.9% of the variability of BEE, and the adjusted coefficient of determination was 83.4%. Standardized coefficients of FFM, fat mass, insulin secretion (CPR6'), use of insulin, and pulse rate in model 2 were 0.82, 0.19, −0.16, −0.15, and 0.15, respectively. Variance inflation factors of variables in model 2 were all <1.5. Other plausible determinants (ie, FPG, mean preprandial PG, A_{1c}, dietary energy, use of sulfonylurea, use of metformin, age, and sex) were not selected as significant contributors by stepwise estimation. The effect of insulin secretion (CPR6') in BEE adjusted for FFM, fat mass, use of insulin, and pulse rate is illustrated in **Figure 1**.

DISCUSSION

In the current study, endogenous insulin secretion and exogenous insulin administered in treatment were both significant independent variables that predicted BEE in Japanese patients with type 2 diabetes under MNT and medications. In addition, both factors were negatively correlated with BEE. The current results suggested that the effect of insulin, regardless of the en-

dogenous or exogenous source, had a significant negative impact on energy expenditure in patients with fair glycemic control under medical care.

In the current study, clinical factors regarding the effects of insulin predicted BEE, whereas factors regarding glycemic control did not predict BEE. The cause of these differing results is not clear, but the present results indicated that the effects of insulin affected BEE independently of glycemia. In a previous report, EGO was shown to be a significant predictor of elevated REE of patients with diabetes after adjustment for body composition, but the glucose concentration was not (18). Although FPG was correlated with EGO, it accounted for only 21% of its variability (19). Gluconeogenesis is an energy-consuming metabolic pathway and is thought to be a major source of increased EGO in diabetes (20–22). Because hepatic insulin deficiency plays an important role in increased gluconeogenesis in diabetes


FIGURE 1. Relation between CPR6' and BEE after adjustment for fat-free mass, fat mass, pulse rate, and insulin use ($n = 58$). BEE, basal energy expenditure; CPR6', C-peptide immunoreactivity 6 min after intravenous glucagon injection.